Literature DB >> 3344538

Effects of CDP-choline on neurologic deficits and cerebral glucose metabolism in a rat model of cerebral ischemia.

M Kakihana1, N Fukuda, M Suno, A Nagaoka.   

Abstract

The effects of cytidine 5'-diphosphocholine (CDP-choline) on neurologic deficits and cerebral glucose metabolism were studied in a rat model of transient cerebral ischemia. Cerebral ischemia was induced by occluding both common carotid arteries for 20 or 30 minutes 24 hours after the vertebral arteries were permanently occluded by electrocautery. CDP-choline was administered intraperitoneally twice daily for 4 days after reestablishing carotid blood flow. CDP-choline at two dosages (50 and 250 mg/kg) shortened the time required for recovery of spontaneous motor activity in a dose-related manner; recovery time was measured early after reperfusion. Neurologic signs were observed for 10 days. High-dose CDP-choline improved neurologic signs in the rats within 20-30 minutes of ischemia. When cerebral glucose metabolism was assessed on Day 4, increases in the levels of glucose and pyruvate were accompanied by decreases in the synthesis of labeled acetylcholine from uniformly labeled [14C]glucose measured in the cerebral cortex of rats with 30 minutes of ischemia. High-dose CDP-choline also attenuated changes in these variables. CDP-[1,2-14C]choline injected intravenously 10 minutes after reperfusion was used for membrane lipid biosynthesis. These results indicate that CDP-choline has beneficial effects on brain dysfunction induced by cerebral ischemia, which may be due in part to the restorative effects of CDP-choline on disturbed cerebral glucose metabolism, probably by stimulating phospholipid biosynthesis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3344538     DOI: 10.1161/01.str.19.2.217

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  11 in total

1.  Cholinergic drugs reverse AF64A-induced impairment of passive avoidance learning in rats.

Authors:  N Yamazaki; K Kato; E Kurihara; A Nagaoka
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

2.  Electrophysiological assessment of glaucomatous visual dysfunction during treatment with cytidine-5'-diphosphocholine (citicoline): a study of 8 years of follow-up.

Authors:  Vincenzo Parisi
Journal:  Doc Ophthalmol       Date:  2005-01       Impact factor: 2.379

3.  Reduction of maturation phenomenon in cerebral ischemia with CDP-choline-loaded liposomes.

Authors:  M Fresta; G Puglisi
Journal:  Pharm Res       Date:  1999-12       Impact factor: 4.200

Review 4.  What animal models have taught us about the treatment of acute stroke and brain protection.

Authors:  S H Ahmed; A Y Shaikh; Z Shaikh; C Y Hsu
Journal:  Curr Atheroscler Rep       Date:  2000-03       Impact factor: 5.113

Review 5.  Limiting neurological damage after stroke: a review of pharmacological treatment options.

Authors:  S J Read; T Hirano; S M Davis; G A Donnan
Journal:  Drugs Aging       Date:  1999-01       Impact factor: 3.923

Review 6.  Cytidine 5'-diphosphocholine (CDP-choline) in stroke and other CNS disorders.

Authors:  Rao Muralikrishna Adibhatla; J F Hatcher
Journal:  Neurochem Res       Date:  2005-01       Impact factor: 3.996

Review 7.  Stem cells: implications in experimental ischaemic stroke therapy.

Authors:  Ashish K Rehni; Inderbir Singh; Nirmal Singh; Manoj Kumar
Journal:  Stem Cell Rev       Date:  2008-05-31       Impact factor: 5.739

Review 8.  Multifunctional actions of approved and candidate stroke drugs.

Authors:  Jens Minnerup; Wolf-Rüdiger Schäbitz
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

9.  Citicoline protects brain against closed head injury in rats through suppressing oxidative stress and calpain over-activation.

Authors:  Ke Qian; Yi Gu; Yumei Zhao; Zhenzong Li; Ming Sun
Journal:  Neurochem Res       Date:  2014-04-02       Impact factor: 3.996

Review 10.  Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly.

Authors:  A R Green
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.